Tredje AP-fonden’s Royalty Pharma RPRX Stock Holding History

Tredje AP-fonden’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Buy	219,990 +35,778	+19%	+$1.86M	0.06%	305
2026 Q1	$8.84M	Buy	184,212 +130,748	+245%	+$5.73M	0.05%	341
2025 Q4	$2.07M	Buy	53,464 +16,545	+45%	+$631K	0.02%	292
2025 Q3	$1.3M	Sell	36,919 -39,546	-52%	-$1.43M	0.01%	327
2025 Q2	$2.76M	Buy	76,465 +25,290	+49%	+$838K	0.02%	185
2025 Q1	$1.59M	Hold	51,175	–	–	0.01%	266
2024 Q4	$1.31M	Sell	51,175 -51,175	-50%	-$1.36M	0.01%	349
2024 Q3	$2.9M	Hold	102,350	–	–	0.03%	298
2024 Q2	$2.7M	Sell	102,350 -20,841	-17%	-$578K	0.03%	294
2024 Q1	$3.74M	Buy	123,191 +14,785	+14%	+$436K	0.04%	243
2023 Q4	$3.05M	Hold	108,406	–	–	0.04%	286
2023 Q3	$2.94M	Sell	108,406 -3,647	-3%	-$108K	0.04%	267
2023 Q2	$3.44M	Sell	112,053 -6,988	-6%	-$237K	0.05%	261
2023 Q1	$4.29M	Buy	119,041 +48,345	+68%	+$1.79M	0.07%	213
2022 Q4	$2.79M	Buy	70,696 +1,971	+3%	+$82.3K	0.05%	293
2022 Q3	$2.76M	Buy	+68,725	New	+$2.94M	0.06%	255

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tredje AP-fonden's RPRX Position: Q2 2026 in Review

Tredje AP-fonden increased its Royalty Pharma (RPRX) stake by 19% in Q2 2026, buying an estimated $1.86M and bringing the position to 219,990 shares worth $12.3M. The position accounts for 0.06% of the portfolio, ranked #305.

Tredje AP-fonden first reported a position in RPRX in Q3 2022 and has held it in 16 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Tredje AP-fonden held 219,990 shares of Royalty Pharma worth $12.3M as of Q2 2026.
Tredje AP-fonden bought 35,778 Royalty Pharma shares in Q2 2026, an estimated $1.86M.
Royalty Pharma made up 0.06% of Tredje AP-fonden's portfolio in Q2 2026, its #305 holding.
Tredje AP-fonden first reported a position in Royalty Pharma in Q3 2022 and has held it in 16 quarters since.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Tredje AP-fonden's 13F filing for Q2 2026, filed 10 Aug 2026.